{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:08:47Z","timestamp":1759972127360,"version":"build-2065373602"},"reference-count":69,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>The American College of Rheumatology and the US Food and Drug Administration co\u2010sponsored a public meeting in May 2022 about challenges in the clinical development of drugs for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), focusing on innovative clinical trial designs, outcome measures, and data collection methods. Recommendations include early dose\u2010ranging studies and use of active comparators. Challenges and opportunities in assessing long\u2010term safety by leveraging real\u2010world data from electronic health records (EHRs) and claims data are discussed, along with insights from European registries and the evolving role of real\u2010world evidence and artificial intelligence in regulatory evaluations. Endpoints for assessing disease activity and outcome measures used in RA and PsA trials are explored, emphasizing challenges in defining remission, assessing clinical response, and evaluating structural progression. The need for outcome measures that better reflect treatment targets and the potential of advanced imaging in future trials are highlighted. Challenges with placebo\u2010controlled trials in RA are discussed and use of non\u2010inferiority clinical trial design, in which new drugs are evaluated with active comparators, is proposed. Pragmatic trials in RA and PsA, employing decentralized approaches, are highlighted for their real\u2010world relevance and administrative efficiencies. Strategies for identifying at\u2010risk populations for RA and the challenges of using EHRs and insurance claims data in drug development are discussed. Registry data and digital health technologies show promise in bridging the gap between clinical trials and real\u2010world effectiveness.<\/jats:p>","DOI":"10.1002\/art.42864","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T22:45:28Z","timestamp":1713221128000},"page":"1323-1333","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17\u201318, 2022"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-4260","authenticated-orcid":false,"given":"Jonathan","family":"Kay","sequence":"first","affiliation":[{"name":"UMass Chan Medical School and UMass Memorial Medical Center  Worcester Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-6134","authenticated-orcid":false,"given":"Nikolay P.","family":"Nikolov","sequence":"additional","affiliation":[{"name":"Food and Drug Administration Center for Drug Evaluation and Research  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Weisman","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the American College of Rheumatology Committee on Research","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30402"},{"key":"e_1_2_4_3_1","article-title":"Guidance for industry. Rheumatoid arthritis: developing drug products for treatment","author":"US Food and Drug Administration","year":"2013","journal-title":"Draft Guidance."},{"key":"e_1_2_4_4_1","article-title":"Guidance for industry","author":"US Food and Drug Administration","year":"2005","journal-title":"Premarketing risk assessment."},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-5823.2009.00078.x"},{"key":"e_1_2_4_6_1","unstructured":"US Food and Drug Administration.Real\u2010world evidence. February 5 2023. Accessed March 4 2024.https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.04.015"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.861"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocw021"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1184919"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1294-0"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_2_4_13_1","unstructured":"Sentinel Initiative.Tofacitinib disease\u2010modifying anti\u2010rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFi) use: a descriptive analysis. February 24 2022. Accessed March 4 2024.https:\/\/www.sentinelinitiative.org\/studies\/drugs\/individual-drug-analyses\/tofacitinib-disease-modifying-anti-rheumatic-drugs-dmards"},{"key":"e_1_2_4_14_1","unstructured":"US Food and Drug Administration.Guidance for industry and FDA staff. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data.2013. Accessed March 4 2024.https:\/\/www.fda.gov\/media\/79922\/download"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216693"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091926"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew053"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031476"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq309"},{"issue":"5","key":"e_1_2_4_20_1","first-page":"S\u2010147","article-title":"The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register\u2010enriched data","volume":"32","author":"Eriksson JK","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10048-008-0156-y"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2812"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60027-0"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa553"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.07.006"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22984"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39945"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41959"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216529"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42347"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0833-4"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220853"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00293-y"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.008"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37939"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0642-z"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.202"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110415"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38083"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088245"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154500"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206015"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208267"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207709"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab628"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac073"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170408"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110007"},{"key":"e_1_2_4_55_1","article-title":"Non\u2010inferiority clinical trials to establish effectiveness","author":"US Food and Drug Administration","year":"2016","journal-title":"Guidance for Industry."},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39626"},{"key":"e_1_2_4_57_1","unstructured":"The National Patient\u2010Centered Clinical Research Network (PCORnet). Accessed March 28 2024.https:\/\/pcornet.org\/data\/"},{"key":"e_1_2_4_58_1","unstructured":"US Food and Drug Administration.Complex innovative trial design meeting program. October 3 2023. Accessed March 28 2024.https:\/\/www.fda.gov\/drugs\/development-resources\/complex-innovative-trial-design-meeting-program"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41417"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105767"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02649-1"},{"issue":"9","key":"e_1_2_4_62_1","article-title":"Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial [abstract]","volume":"74","author":"Deane K","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212763"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02650-8"},{"issue":"1","key":"e_1_2_4_65_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"Boheemen L","year":"2021","journal-title":"RMD Open"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220884"},{"key":"e_1_2_4_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01035-y"},{"key":"e_1_2_4_69_1","unstructured":"US Food and Drug Administration.Digital health technologies for remote data acquisition in clinical investigations. Guidance for industry investigators and other stakeholders. December2023. Accessed March 4. 2024.https:\/\/www.fda.gov\/media\/155022\/download"},{"key":"e_1_2_4_70_1","article-title":"Considerations for the use of real\u2010world data and real\u2010world evidence to support regulatory decision\u2010making for drug and biological products","author":"US Food and Drug Administration","year":"2023","journal-title":"Guidance for industry."}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:36:21Z","timestamp":1759952181000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/art.42864"],"URL":"https:\/\/doi.org\/10.1002\/art.42864","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"type":"print","value":"2326-5191"},{"type":"electronic","value":"2326-5205"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"2024-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}